Wedbush Maintains Outperform On Cepheid, $55 PT
In a research report issued yesterday, Wedbush analyst Zarak Khurshid maintained an Outperform rating on Cepheid (NASDAQ:CPHD) with a price target of $55.
Khurshid said, “We are projecting CPHD to report sales of $111 MM with an EPS loss of ($0.17) when the company reports 3Q14 results on Thursday, October 16, 2014 after the market close (conf. call at 5:00 pm EDT, 888-371-8897, webcast: http://ir.cepheid.com). Wall Street consensus estimates are for $110 MM and a loss ($0.16) EPS. Instrument placements seem ok. Still encouraged by 2014 Infiniti system inflection. Based on our recent checks, we believe there continues to be solid North American and EU instrument demand at the small-medium hospital level. Also, we continue to be encouraged by the y/y trend in Infiniti placements, which included 11, 7 and 21 placements in 2Q14, 1Q14 and 4Q13, respectively.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Zarak Khurshid has a total average return of 0% and a 58.6% success rate. Khurshid has a 11.0% average return when recommending CPHD, and is ranked #2362 out of 3319 analysts.